Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Z Leder

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
The Journal of Clinical Endocrinology and Metabolism|December 12, 2018
Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled TrialsHouchen Lyu, Bakr Jundi, Chang Xu, et al.
The Journal of Clinical Endocrinology and Metabolism|February 13, 2014
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trialBenjamin Z Leder, Joy N Tsai, Alexander V Uihlein, et al.
The American Journal of Clinical Nutrition|July 10, 2015
Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trialDeborah M Mitchell, Benjamin Z Leder, Enrico Cagliero, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 12, 2021
Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With OsteoporosisDavid W Dempster, Hua Zhou, Sudhaker D Rao, et al.
Annals of Internal Medicine|July 28, 2020
Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort StudyHouchen Lyu, Kazuki Yoshida, Sizheng S Zhao, et al.
The Journal of Clinical Endocrinology and Metabolism|September 3, 2022
Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment RatesWuQiang Fan, Melissa Machado, Benjamin Z Leder, et al.
The Journal of Clinical Endocrinology and Metabolism|May 11, 2006
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic menJoel S Finkelstein, Benjamin Z Leder, Sherri-Ann M Burnett, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 22, 2014
Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT StudyJoy N Tsai, Alexander V Uihlein, Sherri-Ann M Burnett-Bowie, et al.
Bone|October 25, 2020
Widespread disturbance in extracellular matrix collagen biomarker responses to teriparatide therapy in osteogenesis imperfectaLindsey Nicol, Priya Srikanth, Kim Henriksen, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2014
Effects of escitalopram on markers of bone turnover: a randomized clinical trialSusan J Diem, Hadine Joffe, Joseph C Larson, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Endocrinology and Metabolism|December 12, 2018
Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled TrialsHouchen Lyu, Bakr Jundi, Chang Xu, et al.
The Journal of Clinical Endocrinology and Metabolism|February 13, 2014
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trialBenjamin Z Leder, Joy N Tsai, Alexander V Uihlein, et al.
The American Journal of Clinical Nutrition|July 10, 2015
Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trialDeborah M Mitchell, Benjamin Z Leder, Enrico Cagliero, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 12, 2021
Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With OsteoporosisDavid W Dempster, Hua Zhou, Sudhaker D Rao, et al.
Annals of Internal Medicine|July 28, 2020
Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort StudyHouchen Lyu, Kazuki Yoshida, Sizheng S Zhao, et al.
The Journal of Clinical Endocrinology and Metabolism|September 3, 2022
Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment RatesWuQiang Fan, Melissa Machado, Benjamin Z Leder, et al.
The Journal of Clinical Endocrinology and Metabolism|May 11, 2006
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic menJoel S Finkelstein, Benjamin Z Leder, Sherri-Ann M Burnett, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 22, 2014
Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT StudyJoy N Tsai, Alexander V Uihlein, Sherri-Ann M Burnett-Bowie, et al.
Bone|October 25, 2020
Widespread disturbance in extracellular matrix collagen biomarker responses to teriparatide therapy in osteogenesis imperfectaLindsey Nicol, Priya Srikanth, Kim Henriksen, et al.
The Journal of Clinical Endocrinology and Metabolism|July 12, 2014
Effects of escitalopram on markers of bone turnover: a randomized clinical trialSusan J Diem, Hadine Joffe, Joseph C Larson, et al.
Pageof 9